To better understand the requirement for interleukin 2 (IL-2) in specific immune responses, we have established the use of cell ablation to selectively eliminate T cells that produce IL-2. To accomplish this we have generated transgenic mice that express the herpes simplex virus 1-thymidine kinase (HSV-TK) gene under the transcriptional control of the murine IL-2 promoter that renders IL-2-producing cells sensitive to the cytotoxic effects of the antiviral drug ganciclovir (GANC). HSV-TK activity was specifically expressed in activated T cells from transgenic mice. When CD4 T cells from transgenic mice were stimulated with the superantigen staphylococcal enterotoxin A (SEA) in the presence of GANC, proliferation and IL-2 production were almost completely inhibited and the activated CD4+VB3 + T cell population, eliminated. Proliferation was not restored by adding IL-2, showing that most proliferating cells are not bystander cells. In contrast, the proliferative response to concanavalin A (Con A) was only partially inhibited by treatment of CD4 T cells with GANC, although the efficiency of eliminating IL-2-producing cells was shown to be comparable with that achieved using SEA. This suggests that a portion of the proliferative response to Con A occurs via an alternative pathway not requiring IL-2 synthesis and release.
T
he proliferation of clones of antigen-specific cells is one of the most important events that occurs during a primary immune response. Since the frequency of antigen-specific precursor T cells is low in peripheral lymphoid organs or in blood, the clonal expansion of antigen-reactive effector cells is critical for the expression of a specific immune response. Such clonal expansion is accomplished by tightly regulating the production of specific lymphokines that can function as growth factors, and by regulating the expression of the receptors for these lymphokines (1).
Antigen-induced T cell proliferation is regulated primarily through the actions of IL-2 on its specific cell surface receptor. IL-2 is a lymphocytotropic hormone released from antigentriggered T lymphocytes within hours of activation. IL-2 mediates a switch in T cells from G1 into the proliferative phases of the cell cycle. Once T cells are stimulated to secrete IL-2, the lymphokine can interact with the same cell from which it was produced (an autocrine effect) or with any other cell that expresses IL-2 receptors (a paracrine effect), leading to clonal expansion (2, 3) .
Although IL-2 remains a most important factor regulating T cell growth, there are clearly IL-2-independent mechanisms that can also regulate T cell proliferation (4) (5) (6) (7) (8) . In addition, murine T helper cells can be divided into subsets based on the pattern of cytokines secreted in response to antigen or mitogen stimulation (9) . Cells of the Thl subset produce IL-2, IFN-% and lymphotoxin, whereas Th2 cells secrete IL-4, IL-5, and IL-6. The different cytokines released by Thl and Th2 clones lead to markedly different functions (10) (11) (12) . Whereas Thl clones require IL-2 as an autocrine growth factor, the growth of Th2 clones involves the autocrine secretion of IL-4, as well as the cofactor IL-1 (13, 14) .
The dichotomy between T helper cells with regard to cytokine production poses the question of lineage relationship between T cells that secrete different cytokines, specifically IL-2, IL-4, and IFN-3,. Although models exist to explain the origins of the distinct functional subsets (15) , it is unknown whether a given subset is derived from the other or if there is a common precursor cell.
To analyze the role of IL-2-producing T cells in T cell development and in a given immune response, we generated transgenic mice which allow the selective ablation of IL-2-producing T cells in vitro. Borrelli et al. (16) showed that the synthesis of HSV-thymidine kinase (TK) 1 in transgenic mice could be used to ablate cells that express this product. We chose this approach because it offers several advantages Abbr~iations used in this paper: GANC, ganciclovir; HSV-TK, herpes simplex virus 1-thymidine kinase; SEA, staphylococcal enterotoxin A. over studies that merely decrease the amount of IL-2 available, such as those that employ anti-IL-2 antibodies (17, 18) or IL-2-deficient mice (19) . First, our approach allows us to determine the proportion of cells that are proliferating in a given immune response that are actually making IL-2 or, alternatively, are bystander cells that require IL-2 for cell growth but are not making IL-2. Second, the transgenic mice we have generated are ideal for studying precursor-product relationships between different cytokine-producing T cells. Finally, the ability to eliminate cells that produce IL-2 enables us to examine the function of these cells in a given immune response, as well as during development. Since our ability to selectively ablate IL-2-producing T cells is based on a toxic phenotype that is cell specific and inducible, these cells can be eliminated during different stages of development or of an immune response (i.e., during priming or during a recall response). More importantly, an inducible toxic phenotype allows us to study the function of a cell without interfering with the development of that cell.
We establish here that ablation is specific for cells that are proliferating in response to mitogenic stimulation, and that the cells that are not activated or do not produce IL-2 are not eliminated. This new approach also reveals an interesting difference between the requirement for IL-2-producing cells in the proliferation induced by Con A versus staphylococcal enterotoxin A (SEA) stimulation.
Materials and Methods
Gene Constructs and Transgenic Mice. The plasmid pATgMIL2-A containing the murine Ib2 gene was obtained from Drs. Erik Reraaut and Waiter Fiefs (University of Ghent, Belgiura) (20) . The 2.7-kb Ib2 promoter was isolated by EcoRI-Pst restriction digestion of pATgMIL2-A. This fragment contains the TATA box and the DNase hypersensitive site located at -275 that have been shown to be necessary for transcription (21) . The IL-2 promoter was linked to a 1.5-kb BgllI-HindIII fragment of the HSV-1-TK gene (22) via a Pst-BgllI linker to generate the construct pIb2TK. The recombinant DNA pIL-2TK was injected into C57BL/6 x SJL F2 fertilized mouse eggs by the Yale Transgenic Facility. Five positive founder lines were established. The founder lines were back-crossed onto C57BL/6 mice (The Jackson Laboratory, Bar Harbor, ME) to obtain progeny for these studies.
Cell Lines. The TK § cell line was a generous gift of Dr.
Wilma Summers (Yale University, New Haven, CT) and has been described (23) .
Antibodies, Cytokines, and Reagents. Supernatants from the antiThy-1 hybridoraa Y19 (24) and the raAb 212.A1 (anti-I-Ab) (25) were generated at Yale University. The antibodies TIB105 (anti-CD8), TIB146 (anti-B220), and HB191 (anti-NK cell) were obtained from the American Type Culture Collection (gockville, MD). PE-conjugated anti-CD4 raAb was purchased from Becton Dick- The standard assay for TK was obtained from Summers and Summers (23) and modified slightly. The assay included 0.1 M sodium phosphate, pH 6., 0.01 M ATP, 0.01 M magnesium acetate, 0.025 M NaF. The substrate nSI-deoxycytidine (dC) (100 #Ci/0.4 ml; New England Nuclear, Boston, MA) was used at 0.5 #Ci per 50/zl reaction. The dC deaminase inhibitor THU was added to a final concentration of 50 #g/ml. 10 #1 ceU extract was used in each reaction and the assay was run at 37~ Incorporation of labeled substrate was determined by absorption of 10 #1 of the reaction to DEAE paper disks that were washed in water 3 x 15 rain and in ethanol 15 rain, air-dried, and counted in a liquid scintillation counter (model LS2800; Beckman Instruments, Inc., Fullerton, CA).
Cell Growth Assay. The cytotoxicity of the drug GANC was determined by using a cell growth assay. To obtain CD4-enriched T cells, total spleen cells were incubated for 60 rain at 4~ with an antibody cocktail containing T1B105 (anti-CD8), T1B146 (anti-B220), HB191 (anti-NK cell), and 212.A1 (anti-l-Ab). Cultures were subsequently incubated with magnetic anti-mouse IgG (Collaborative Research, Inc., Bedford, MA) for 20 rain at 4~ and then passaged over a magnet three times. To obtain CD8-depleted cultures, the same procedure was followed except that T1B105 was the only antibody used. On average, 70% enrichment of CD4 cells was obtained.
To deplete cultures of T cells for generating APCs, total spleen cells were resuspended directly in supernatant from a Y19 (antiThyl) hybridoraa and incubated for 60 rain at 4~ The cells were then treated with rabbit complement (Low-Tox-M; Cedarlane Laboratories Ltd., Hornby, ON, Canada) at 37~ for 30 rain. To obtain syngeneic APCs, complement-lysed cultures were irradiated (2,500 tad).
CD4 cells from transgenic and control mice were cultured in a volume of 200 #1EHAA medium with 10% FCS in flat-bottomed 96-well plates (Costar Corp.). Where indicated, 104 APCs were added to each well. Unless otherwise indicated, GANC was used at 10/zM, To measure proliferation for SEA (100 ng/ral)-stimulated cells, 1 #Ci [3H]thymidine was added on day 6 of culture and cultures were harvested on day 7 using a harvester (Pharmacia LKB Biotechnology Inc., Piscataway, NJ). Ceils treated with Con A (2.5 #g/ml) were pulsed on day 3 and harvested on day 4.
Cytokine Assay. The CTLb2 cell line was obtained from Dr. In Situ Hybridization. The Ib2 probe, kindly provided by Dr.
V. Paetkau (University of Alberta, Alberta, Canada), corresponded to a full-length cDNA clone (26) . In situ hybridization was carried out on cytocentrifuge preparations of mitogen-stimulated CD4 T cells using 3sS-labeled R.NA sense or anti-sense transcripts essentially as described (26, 27) . Before hybridization, stored slides were rehydrated, acetylated, and prehybridized at 50~ for 2 h. The slides were then dehydrated and hybridized at 50~ for 16 h. The hybridized slides were washed and dehydrated, and autoradiography was performed as described (26) .
Results

Spleen Cells Isolated from Transgenic Mice Express HSK-TK
Activity. To establish transgenic mice that allow the selective ablation of IL-2-producing T cells, the HSV-TK gene was placed downstream of the murine IL-2 promoter to direct expression of the HSV-TK gene (Fig. 1) . The treatment of cells that express HSV-TK with an antiviral agent such as GANC results in cell death (16) . Five positive founder lines were identified using Southern blot analysis.
To determine the level of HSV-TK activity expressed, TK assays specific for the viral enzyme were carried out. In the presence of T cell activation and subsequent IL-2 produc- tion, the HSV-TK gene should be expressed. Total spleen cells were isolated from each transgenic line and cultured for 42 h in the presence or absence of Con A; cell extracts were assayed for HSV-TK activity (Fig. 2 ). An HSK-TK positive cell line was used as a positive control for the assay. The transgenie lines 529, 531, and 539 show substantial HSV-TK activity in the presence of Con A as compared with the B6 control. In the 529 pedigree (which has the highest copy number), expression of HSV-TK appears to be at least partly constitutive since HSV-TK activity can be detected in the absence of Con A stimulation. Two other founder lines, 536 and 726, had low to zero HSV-TK activity (data not shown).
Cell-specific Expression of nSV-TK Activity. To determine whether the transgene was expressed specifically in T cells, total spleen cells were isolated from the 539 pedigree and separated into T and B cells. T cells were cultured in the presence or absence of Con A and B cells were incubated with or without LPS. Significant TK activity was only present in cell extracts prepared from T cells stimulated with Con A (Fig.  3) , not in transgenic B cells or B6 control cells. The B and T cells were activated by LPS and Con A, respectively, since they proliferated in response to the specific stimulus (data not shown).
Specific Killing ofT Cells Isolated from Transgenic Mice Using GANC.
To evaluate the e~cacy of our system, the toxicity of GANC to T cells expressing the HSV-TK gene was tested in vitro. For GANC to kill T cells, the IL-2 promoter must be activated to allow HSV-TK expression. Though it is not dear to what extent chromosomal damage must occur to result in cell death, toxicity is very likely dependent on both GANC concentration and length of treatment. For these Figure 3 . HSV-TK activity in T and B cells. Total T and B cells were obtained as described in Materials and Methods. 107 T or B cells were cultured with 2.5/xg/ml Con A or 50 #g/ml LPS, respectively, for 42 h. Cells were harvested and lysed in assay buffer and 50-/~1 reactions were run as described in the legend to Fig. 2 . The incorporation of the substrate 12SI-deoxycytidine was determined after 3 h of incubation at 37°C by absorption of 10/~1 of the reaction to DEAE paper and counting on a liquid scintillation counter. 106 TK + cells were used as a positive control.
reasons, SEA was chosen for T cell activation. SEA is a superantigen which, when combined with MHC class II molecules, is a powerful stimulator of T cells via the VB element of the TCR (28) . When unprimed splenic T cells are incubated in the presence of SEA, maximum proliferation is accompanied by a large production of IL-2 (data not shown). GANC treatment suppressed proliferation to SEA of CD4 T cells from transgenic lines 529, 531, and 539 (Fig. 4) showing that the proliferating cell has been ablated. Proliferation of T cells from the control B6 mouse is not inhibited in the presence of the drug. The transgenic lines 539 and 529 were chosen for their high HSV-TK activity and sensitivity to GANC. However, since the 529 pedigree shows some constitutive HSV-TK activity (Fig. 2) , most experiments in this study were performed using the 539 mice.
Titration of GANC Concentration. To determine the optimum concentration of GANC, CD4-enriched T cells derived from 539 transgenics and control mice were cultured in the presence of SEA and various concentrations of GANC (Fig. 5) . Suppression was partial at 1 #M GANC but increased to 89% at 10/~M GANC in CD4 cells from the transgenic mouse. An insignificant level of nonspecific inhibition (4%) of cells from the control mouse also occurred at 10/~M but increased significantly at 50-100 #M GANC. Similar results were observed with total spleen cells (data not shown). A concentration of 10/~M GANC was therefore selected for this study (unless otherwise noted).
Titration of Cell Number. The inhibitory effect of GANC on the ability of CD4 T cells to proliferate in response to
• Figure 4 . Suppression of proliferation in the presence of GANC. Spleen cells were depleted of CD8 cells and plated at 2.5 x 104 cells/well. Cells were activated using 100 ng/ml SEA in the presence or absence of 10/~M GANC. Cells were pulsed with [3H]thymidine (1/~Ci) on day 6 and incorporation was measured on day 7. Samples were run in duplicate and the maximum average cpm obtained was 189,634.
SEA is titratable with cell number (Fig. 6 ). The suppression of proliferation ranged from 85% using 5 x 104 cells to 98% using 1.25 x 104 cells. These results further demonstrate the importance of IL-2-producing cells in the proliferative response to SEA.
Elimination of lL-2 Production by the Ablation of TK-Expressing Cells.
As an additional estimate of the effaciency of elimination of IL-2-producing cells, we stimulated IL-2-TK T cells with SEA plus or minus GANC and determined the amount of IL-2 produced as a function of input cell number ( 
Cell Number
Suppression of proliferation is titratable with cell number. Various numbers of CD4-enriched spleen cells were cultured with 100 ng/ml SEA and 104 APC in the presence or absence of 10/zM GANC. Cells were pulsed with [3H]thymidine (1/~Ci) on day 6 and incorporation was measured on day 7. Samples were run in triplicate and the SE is given. The maximum average cpm obtained was 347,305. 7). The presence of GANC in the culture medium reduced the IL-2 secreted by about 80-90%. The efficiency of the IL-2-TK system is therefore ",,80-90%, whether measured by elimination of proliferation (Fig. 6 ), IL-2 production (Fig.  7) , or the elimination of cells expressing IL-2 mRNA measured by in situ hybridization (see Table 2 ). GANC, harvested on days 4 and 6, and double stained for CD4 and V/33 expression (Table 1 , Fig. 8 ). Using this scheme, the cells were divided into CD4+V33 +, CD4+V33 -, CD4-V/33-, and CD4-V~3 + populations. As expected, the percentage of CD4 +V33 + T cells increases substantially following SEA stimulation, as compared with the starting population. The CD4-V33 + population also increases after stimulation with SEA, particularly on day 6 (these cells are most likely CD8 cells that are positive for V133 expression). Whereas GANC treatment has no effect on cells isolated from the B6 control mouse, there is a significant decrease in the number of V133 + T cells in samples from the transgenic mouse. On day 4, all V33 + T cells are significantly reduced whereas predominantly CD4+V33 + cells are affected on day 6. There are more V33 + cells on day 6 as compared with day 4 (Fig. 8) . This may represent an enrichment of a small population of V33 + cells which initially escaped killing by GANC. As expected, there is no effect on CD4-V~/3-T cells. These cells are most likely B cells that do not express HSK-TK activity. Whereas there is a selective ablation of V133 + T cells, there is also killing of CD4+VI33 -cells. The non-V133 CD4 cells that are eliminated are most likely other CD4 cells that respond to SEA such as V1311 T cells (29) . It is interesting to note that although we generally see an 80-90% suppression of proliferation in cell growth assays, this is not reflected in the decrease seen in the CD4 T cell population. A possible explanation is that these residual cells are CD4 cells that are not synthesizing IL-2 and are therefore not affected by GANC. It is also interesting that CD4 + V133 + T cells are preferentially eliminated on day 4, whereas a greater percentage of CD4+VB3 -cells are ablated on day 6. It is likely that the V133 + population responds to SEA before other VI3-expressing T cells. 
V/33 T Cells Activated by
IL-2-producing Cells Are Required for a Proliferative Response to SEA but Are only Partially Required for a Response to Con A.
To investigate the requirement of IL-2-producing cells in response to mitogens other than SEA, CD4 T cells from the transgenic mouse were stimulated with Con A. Fig. 9 compares the proliferative response of CD4 cells treated with GANC when stimulated with either SEA or Con A. GANC reduced proliferation of transgenic CD4 cells to SEA by 83%. When CD4 cells were stimulated with Con A, proliferation was suppressed by only 35% in cells from the transgenic mouse and 9% in cells from a control mouse (Fig. 9 B) . The difference in the effect of GANC on proliferation when cells are stimulated with Con A as compared with SEA could reflect differences in the mechanisms by which cells are activated by the two mitogens, or merely differences in the efficiency of killing in the two systems. The proliferation to Con A could involve IL-2-independent mechanisms; such cells would be insensitive to the effects of GANC. To test this hypothesis, cells were hybridized in situ after activation with either Con A or SEA in the presence or absence of GANC. Cells were analyzed for IL-2 mRNA expression after primary stimulation and after restimulation with the same mitogen. It is striking that the reduction in the proportion of cells expressing IL-2 mRNA in the primary cultures is nearly identical for both Con A-and SEA-activated cells (Table 2). Since the efficiency of eliminating cells that produce IL-2 is the same for both mitogens, the difference in the effect of GANC on proliferation is not a result of less efficient killing of Con A-treated cultures as compared with SEA. These results are consistent with there being an IL-2-independent mechanism of proliferation for Con A which is insensitive to drug treatment. Upon restimulation, a small number of cells are capable of IL-2 expression following GANC treatment for both Con A and SEA (Table 2 ). These residual ceils appear to be qualitatively different from cells not treated with drug since they have a lower grain count and therefore presumably lower IL-2 mRNA content. These cells may not be susceptible to GANC because they produce less IL-2 and are consequently unable to proliferate, which is necessary for killing with GANC. Consistent with this is the fact that proliferation of SEAstimulated cells is significantly inhibited by GANC.
The Proliferating T Cell Is the Same Cell Making IL-2.
In the present study, cells that produce IL-2 are ablated and, as a consequence, proliferation is reduced. If bystander cells which require IL-2 for proliferation, but which do not produce it, are still present in the culture, these cells could proliferate in response to IL-2 since they will not be killed by GANC. To test this, 5 U/ml (5 ng/ml) rlL-2 was added to CD4 cells stimulated with SEA in the presence or absence of GANC. Fig. 10 compares the results of proliferation assays carried out using cells from a control (Fig. 10, A and B) or a transgenic (Fig. 10, C and D) mouse incubated with or without added IL-2. In the absence of rlL-2, proliferation was suppressed in the transgenic mouse from 67% using 5 x 104 cells to 89% using 1.25 x 104 cells (Fig. 10 C) . When rlL-2 was present during the incubation period, proliferation was suppressed from 86% using 1.25 x 104 cells to 91% using 2.5 x 104 or 5 x 104 cells (Fig. 10 D) . The same failure to restore proliferation was obtained when 10 U/ml (IL-2) was added to GANC-treated CD4 cells (data Discussion IL-2 has been shown to be the major growth factor for T cells and plays a key role in the clonal expansion of antigenspecific T cells. There are indications, however, that IL-2 is not the sole T cell growth factor and that IL-2-independent mechanisms may exist for T celI proliferation.
We have established the use of cell ablation to analyze the requirement for IL-2-producing cells in the proliferative responses to mitogens. Treatment with GANC is highly effective (,'080-90%) in the removal of IL-2-producing cells, whether measured by suppression of T cell proliferation or IL-2 production, or the elimination of cells expressing IL-2 mRNA detected by in situ hybridization. The results presented here demonstrate that IL-2-producing T cells are required for a proliferative response to the superantigen SEA. We have also shown that proliferation to SEA is not restored when rlL-2 is added to cultures in which IL-2-producing cells have been eliminated. These results indicate that the majority of T cells that proliferate in response to SEA are making IL-2 and are not bystander cells which require IL-2 for cell growth. A less likely explanation which we have not excluded, however, is that the IL-2-producing cells provide something other than IL-2, which is required for proliferation by bystander cells.
The inability of rlL-2 to restore the proliferative response to SEA differs from results reported by Schorle et al. (19) . When IL-2 was added to Con A-stimulated splenocytes isolated from mice that were unable to make IL-2 as a consequence of a homozygous null mutation at the IL-2 locus, proliferation was restored to wild-type levels. However, in these IL-2-deficient mice, the cells that respond to IL-2 are still present and able to proliferate when exogenous IL-2 is added. In the study described here, the cells that require IL-2 for proliferation to SEA have been ablated.
The ablation method used in this study only partially inhibits the proliferative response to Con A, whereas it nearly abolishes the response to SEA. Using in situ hybridization, we have shown that the efficiency of killing of cells that produce IL-2 is the same for Con A and SEA, despite the different effect on T cell proliferation. This suggests that a portion of the proliferative response to Con A occurs via an alternative pathway not requiring IL-2 expression and release. These results are consistent with those obtained by Schorle et al. (19) using IL-2-deficient mice. Although splenocytes isolated from such mice show a marked decrease in their ability to respond to Con A, there is still a residual proliferative response that is not inhibited by the absence of IL-2. Our results also demonstrate that residual cells capable of IL-2 expression are present after drug treatment when either mitogen is used for stimulation. However, the lower grain count present in these cells compared with cells not treated with the drug suggests that these cells may be unable to proliferate because of a reduced production of IL-2, which renders them insensitive to GANC.
